Peripheral artery disease (PAD) is a prevalent global problem with increased mortality. Affects about one in four patients with end stage renal disease (ESRD). Intermittent pneumatic compression (IPC) has shown improvement of lower extremity hemodynamics and symptoms and may be implemented during hemodialysis (HD). We designed a trial to test the utility of IPC in the ESRD population by assessing improvement in quality of life (QOL) and functional limitation from PAD-related symptoms. We aim to present our design and initial results. Methods: This is a prospective single cohort study for paired analysis undergoing recruitment of outpatients at the HD unit of John H. Stroger, Jr. Hospital of Cook County. A sample size of 78 yields a power of 80% and alpha of 0.05, assuming an average peak walking time of five minutes and 25% improvement after supervised exercise. PAD is confirmed by ankle-brachial index (ABI) and demographics collected. A baseline Six-minute Walk Test (6MWT), Peripheral Artery Questionnaire (PAQ) and Walking Impairment Questionnaire (WIQ) are administered and will be compared with their performance post intervention. The IPC device (Bio Arterial Plus) will be used for intervention during each HD for two months average. We present continuous variables as mean±SD and categorical variables as percentage. Results: From 10 recruited patients in the first month, 60% are men, age 54.6±13.1 years, the majority Hispanic (80%). 70% of ABI were abnormal, all due to non-compressible PAD (1.44±0.20). All patients have HTN, 50% diabetes, 20% hyperlipidemia, 10% had a stroke and 10% revascularization for PAD. At baseline 6MWT, distance walked was 357.7±59.5 m, with 600±52.5 total steps and fatigue as main symptom (30%) and no typical claudication. QOL questionnaires showed WIQ walking distance 68.58±18.04, WIQ walking speed 72.5±26.36, and WIQ stair climbing 50.04±30.04 points; PAQ physical limitation 61±21.4, PAQ symptoms 62.79±18.7, PAQ satisfaction 68.67±27.9, PAQ quality of life 64±13.04, and PAQ social limitation 70±23.13 points. Conclusion: Non-compressible PAD is prevalent in ESRD, and QOL seems significantly compromised from it. Our trial will provide insight of an alternative therapy, and optimize the time in HD even further.